Novocure Inc. disclosed that CMS had revoked its billing privileges for the company’s products, retroactive to December 17, 2025, due to an administrative issue with its triannual re-validation rather than any substantive failure to qualify. While Novocure has submitted a Corrective Action Plan and continues to treat existing and new patients, it cannot bill Medicare, Medicare Advantage and other CMS-related payors during the revocation period and estimates that it will be unable to recognize roughly $13 million in monthly revenue from these payors until billing privileges are restored, with the timing, ultimate resolution and extent of recoverable revenue for services rendered in the interim remaining uncertain.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.